| Trial ID: | L3539 |
| Source ID: | NCT00494767
|
| Associated Drug: |
Gw869682
|
| Title: |
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Obesity
|
| Interventions: |
DRUG: GW869682|DRUG: GSK189075|DRUG: GSK189075-Placebo|DRUG: GW869682-Placebo
|
| Outcome Measures: |
Primary: Body fat and fat-free mass as determined by a new investigational MR technique compared to 4C Model methodologies., Measurements at week 8 will be compared to measurements from Day -1 | Secondary: Safety (caloric losses body weight, body composition, weight and hip circumference.), throughout study (Days 1-56)|Leptin levels in serum, at several points during study|Drug levels in blood over time (Day 42 PK parameters are AUC, Cmax, tmax), Day 42
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
27
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: |Primary Purpose: TREATMENT
|
| Start Date: |
2006-09-29
|
| Completion Date: |
2007-06-07
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-07
|
| Locations: |
GSK Investigational Site, Cambridge, Cambridgeshire, CB2 2GG, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT00494767
|
